A common supplement is getting fresh scrutiny in oncology
Biotin supplements are widely marketed for stronger hair and nails, and that message has found a receptive audience among cancer patients coping with treatment-related hair loss. But clinicians at Ohio State University are warning that the vitamin can create a more serious problem: inaccurate lab results that may interfere with care.
The concern, described in material released through ScienceDaily, comes from Brittany Dulmage, an oncodermatologist at The Ohio State University Comprehensive Cancer Center and associate director of dermatology at the College of Medicine. Dulmage argues that the perceived harmlessness of biotin has obscured a meaningful clinical risk. In her view, the supplement can distort blood markers in ways that affect how doctors assess recurrence or make treatment decisions.
That makes this a medical communication problem as much as a supplement problem. Many patients start taking biotin on their own after seeing recommendations online, hearing about it from friends, or sometimes even receiving informal advice in clinical settings. The result is that a routine attempt to address hair loss can spill into the diagnostic side of cancer care.
Why patients take it and why doctors are worried
Hair loss remains one of the most distressing side effects associated with cancer treatment. It is therefore unsurprising that patients look for accessible options that appear low-risk. Biotin, also known as vitamin B7, is commonly associated with keratin production, which is linked to hair, skin and nails. That marketing narrative has helped turn it into a familiar over-the-counter choice.
The problem is that the evidence supporting oral biotin for cancer-related hair or nail regrowth is weak, according to the source material. At the same time, the potential downside is not theoretical. Dulmage says the supplement may produce inaccurate lab results, with the possibility of delaying or changing treatment plans.
In cancer care, even modest distortions in test interpretation can matter. A biomarker that appears normal when it should not be, or abnormal when it is not, can shape follow-up timing, further testing and clinical confidence. The warning here is not that biotin causes cancer progression. It is that it may cloud the information doctors rely on to monitor patients.
The larger issue is disclosure
One reason this risk persists is that supplements often sit outside the way patients think about medications. People may mention prescriptions during appointments but omit vitamins, hair products or over-the-counter regimens because they assume those items are minor. Dulmage’s comments suggest that biotin falls squarely into that blind spot.
That matters because true biotin deficiency is uncommon. The vitamin is already found in foods including fruits, vegetables, meat, eggs and dairy products, according to the source text. If deficiency is rare and evidence of benefit for treatment-related hair loss is limited, the threshold for accepting testing interference should be very low.
Dulmage authored a paper in JCO Oncology Practice to push for more direct conversations between oncologists and patients about hair loss and supplement use. That recommendation points to a practical fix: normalize the discussion early rather than waiting for a lab anomaly or a confusing result.
Key takeaways from the warning
- Biotin is commonly used by patients trying to address cancer-related hair loss.
- The source material says there is little scientific evidence that oral biotin helps with that problem in this setting.
- Doctors are concerned the supplement can interfere with lab testing and distort blood markers.
- The risk is serious because inaccurate results can affect treatment timing and decision-making.
Why this matters beyond one vitamin
The biotin warning also illustrates a broader challenge in modern cancer care. Patients increasingly manage symptoms with information gathered from the internet, social media and wellness marketing. Some of that information is useful. Some of it is incomplete. And some of it can become risky when it interacts with testing, treatment schedules or clinician assumptions.
Supplements occupy a particularly difficult category because they are often framed as supportive rather than pharmacologically meaningful. That framing encourages self-prescribing behavior. But in a tightly managed care pathway, a substance does not need to be powerful in the traditional sense to cause trouble. It only needs to alter measurement.
From a systems perspective, this is why disclosure and counseling matter. The goal is not merely to tell patients what not to take. It is to replace vague assumptions with explicit guidance tied to real clinical consequences. Patients dealing with visible side effects such as hair loss are trying to solve a quality-of-life problem. If clinicians do not offer that conversation, the supplement market will.
A narrow but important message
The warning from Ohio State is also notable for its restraint. It does not claim every patient taking biotin will experience a harmful outcome, and it does not portray the supplement as universally dangerous. Instead, it makes a narrower and more actionable point: in the context of cancer care, a widely used vitamin may offer uncertain benefit while creating avoidable diagnostic confusion.
That is enough to justify more caution. For oncologists, it argues for asking directly about supplement use when discussing hair loss, skin changes and nail changes from treatment. For patients, it is a reminder that over-the-counter products still belong in the medical conversation.
In a treatment setting where timing, monitoring and interpretation all matter, even a familiar vitamin can become clinically significant. The most important shift may simply be recognizing that supplements marketed as harmless beauty aids can have consequences well outside the mirror.
This article is based on reporting by Science Daily. Read the original article.
Originally published on sciencedaily.com
